Abemaciclib, durvalumab and aromatase inhibitor
Phase 1Withdrawn 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer Female
Conditions
Breast Cancer Female, Locally Advanced Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast
Trial Timeline
Oct 1, 2019 → Dec 31, 2020
NCT ID
NCT04088032About Abemaciclib, durvalumab and aromatase inhibitor
Abemaciclib, durvalumab and aromatase inhibitor is a phase 1 stage product being developed by Eli Lilly for Breast Cancer Female. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04088032. Target conditions include Breast Cancer Female, Locally Advanced Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04088032 | Phase 1 | Withdrawn |
Competing Products
20 competing products in Breast Cancer Female